Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Tempest Therapeutics ( (TPST) ) has issued an announcement.
Tempest Therapeutics announced a strategic shift on June 5, 2025, transitioning key executives to consulting roles to explore strategic alternatives and extend capital resources. This move includes severance benefits and accelerated equity awards for the executives, with no disagreements reported between them and the company.
The most recent analyst rating on (TPST) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tempest Therapeutics stock, see the TPST Stock Forecast page.
Spark’s Take on TPST Stock
According to Spark, TipRanks’ AI Analyst, TPST is a Underperform.
Tempest Therapeutics scores low primarily due to its financial performance, marked by a lack of revenues and high expenditures, leading to ongoing losses. The technical analysis indicates a bearish trend, further impacting the score. Valuation metrics are challenging to apply due to the negative earnings, typical for its growth stage. Overall, the stock presents high risk with potential for high reward contingent on future developments.
To see Spark’s full report on TPST stock, click here.
More about Tempest Therapeutics
Tempest Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company is engaged in exploring strategic alternatives to extend its capital resources.
Average Trading Volume: 58,208
Technical Sentiment Signal: Sell
Current Market Cap: $25.39M
For an in-depth examination of TPST stock, go to TipRanks’ Stock Analysis page.